Objectives: Currently in China, celecoxib is prescribed to patients with gastrointestinal bleeding or perforation history. The aim of this study was to model the effect of expanding access to all osteoarthritis (OA) patients in China. MethOds: We created a one-year budget impact model from a payer perspective comparing two scenarios. The first scenario (A) restricts the use of celecoxib to only patients with gastrointestinal bleeding or perforation history while the second scenario (B) does not restrict usage. In (A), patients were prescribed either diclofenac or celecoxib, but those prescribed celecoxib were only dispensed celecoxib if they had gastrointestinal bleeding or perforation history. Those prescribed celecoxib but not fitting the criteria were dispensed diclofenac. In (B), all prescriptions were dispensed as written. For both scenarios, celecoxib and diclofenac prescriptions were written 16.2% and 8% of the time, respectively. Patients with gastrointestinal bleeding or perforation history made up 5.58% of the OA population. Celecoxib was associated with a 20% copay while diclofenac did not have a copay. The base case scenario assumes 13,333 patients. Results: Going from (A) to (B), the total cost of celecoxib increased ¥2,679,866 (94.42%) while the total cost of diclofenac decreased ¥1,817,170 (65.66%). The incremental total cost of drugs increased ¥862,697 (29.48%). The impact on a payer's plans for the year was only due to drug costs since the cost to administer prior authorization was not considered. The per member per month increased ¥0.07 from ¥0.24 to ¥0.32. cOnclusiOns: The expanded access scenario (B) resulted in slightly higher drug costs to the payer, which may be acceptable under most thresholds. Patient outcomes should also be considered to fully understand the impact of removing the gastrointestinal bleeding and perforation history stipulation. (67%) in the study population were on combination of two DMARDs. Most frequently prescribed two DMARDs combination was methotrexate and hydroxychloroquine (64%). Average total cost per prescription was found to be 763.39, while average hospital and out of pocket expense were 281.12 and 482.88 respectively. cOnclusiOns: The drug use pattern in RA was found to be DMARDs based and majority of the cost was borne by the patient. The total increase in cost was due to administration of drugs to treat the adverse drug reaction. Prospective studies in a larger number of patients are needed to assess the utility of prescription audit and cost analysis of drugs used in RA.
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PMs10 the costs of Major anD Minor cycling acciDents in tasMania, australia
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University of Tasmania, Hobart, Australia
Objectives: To estimate the societal costs of cycling accidents in Tasmania, Australia. MethOds: Between July 2011 and March 2012, 136 regular cyclists completed a telephone-based questionnaire. Information collected included demographics, cycling habits and details of major (requiring medical treatment or days off work) and minor (not requiring medical treatment or whole days off work) cycling accidents. The societal costs of accidents in 2011 Australian Dollars ($) were estimated from self-reported medical resource consumption and lost work and leisure time, combined with published medical resource unit costs and salary data. Results: Participants reported 59 major accidents in 5 years preceding the interview, and 27 minor accidents in the previous 12 months. The mean total costs per major accident were $12,158, including direct medical costs $2,228, direct non-medical costs $372, resulted in 3.7 days off work equating to indirect costs of $6,027 and 54.5 days of lost leisure time equivalent to $3,531. The average costs of a minor accident were $632 and included direct non-medical costs of $225, productivity losses of $117 and 5.2 days of lost leisure time valued at $290. The total annual costs to society of major cycling accidents in Tasmania were estimated at $4,123,445. cOnclusiOns: Costs resulting from both minor and major cycling accidents are substantial. The costs of improvements to cycling infrastructure/safety may be offset by reduced costs to society of cycling accidents. 'an, Xi'an, China Objectives: To observe the effect of Iguratimod (T-614) on peripheral blood mononuclear cells (PBMCs),Th1 cells and the expression level of IL-8 of rheumatoid arthritis (RA) patients, and to explore the possible mechanism of T-614 in treating RA. MethOds: 6 patients were diagnosed with RA referred to Department of Rheumatology, The Fifth Hospital of Xi'an. They were evaluated by the score of VAS, DAS28 and the response rates of ACR20/70, respectively. PBMC were prepared from 6 patients in active stage of RA. and treated with T-614 at different concentration (lower dose: 100ug/ml; Higher dose: 1mg/ml ) for 1h and 24h. Flow cytometry (FCM) were performed to examine the apoptosis of PBMC and the level of IFN-γ secretion by T cells. Results: We found that: We found that: 1) Iguratimod effectively induced apoptosis in PBMCs in 1h treatment, T-614 100ug/ml was 19.3±2.8% and 1mg/ml 26.4±3.1%,(P< 0.05); 2) Compared with control, Iguratimod effectively inhibit CD3+ T cell secretion at 24h, T-641(1mg/ml) 1.33±0.12% and control (without T-614) 2.91±0.13% P< 0.05). 3) Levels of IL-8 in the supernatant of T-614 treated group and control group were tested by ELISA, Iguratimod effectively inhibit IL-8 prodcution and there were significant differences (P< 0.05). cOnclusiOns: The results suggest that T-614 induced PBMC apoptosis and decreasing CD3+ T cell IFN-γ production and secretion of IL-8 in peripheral blood might be the possible mechanism of the effective of T-614 in treatment of RA.
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Objectives: The objective of this pilot study was to assess the barriers to the treatment of Osteoporosis in post-menopausal women, from both a physician and patient perspective.
MethOds: An open-ended structured survey was conducted for Physicians and patients across suburban areas of Mumbai. Questionnaires were designed to have questions on incidence of fractures, assessment methods for treatment, treatment regimen, for physicians, and history of fractures and compliance to treatment for patients, identified thorough review of the literature. Descriptive statistics were performed. Objectives: The prevalence of both lifestyle-related metabolic disorders and osteoporosis is increasing in Asia. The aim of this systematic review was to summarise all published studies within Asia on the association between disorders of glucose and fat metabolism (type 2 diabetes, hyperglycemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, metabolic syndrome (MetS) and atherosclerosis) and risk of fracture and osteoporosis. The relationship between metabolic disorders and bone mineral density (BMD) was also examined. MethOds: EMBASE (including MEDLINE) and the Cochrane Library were searched. Only studies conducted within Asia (including East, South-East and South Asia and the MiddleEast), which reported multivariate analysis with a sample size ≥ 200 subjects, were included. Results: A total of 33 studies were included, of which 32 were assessed as adequate and one high quality based on SIGN criteria. All seven studies examining diabetes and fracture found that subjects with diabetes had a higher risk of fracture compared with subjects without diabetes (risk estimate range: 1.26 to 4.73). In contrast, no association was found between diabetes and BMD, although a high degree of heterogeneity was observed. Two studies found that subjects with atherosclerosis had higher risk of fracture (risk estimate range: 1.10 to 2.52). Included studies consistently reported that MetS is likely associated with osteoporosis or decreased BMD in men but not women. There was limited evidence investigating lipid metabolism and hyperglycemia and risk of fracture or bone loss. cOnclusiOns: These findings suggest that diabetes is a risk factor for fracture in Asian populations. Atherosclerosis may also be associated with increased fractures in Asian populations, and MetS associated with bone loss in
